Skip to Content

'
Ana Aparicio

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
P.O. Box 301439
Department of Genitourinary Medical Oncology, Unit 1374
Unit Number: 1374
Houston, TX 77230-1439
Room Number: Cancer Prevention Building, CPB7.3512
Phone: 713 563-6969
Fax: 713/745-1625

Education & Training

Degree-Granting Education

1995 Universidad Autonoma de Madrid, Madrid, Madrid, Spain, MD, School of Medicine

Postgraduate Training

7/2000-7/2003 Medical Oncology Fellowship,, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Keck School of Medicine, Los Angeles, CA
6/1997-6/2000 Internal Medicine Residency, UCLA-West Los Angeles VA Medical Center, Los Angeles, CA
4/1996-4/1997 Medical Oncology Residency,, Hospital Universitario Doce de Octubre, Universidad Complutense de Madrid,, Madrid, Spain

Board Certifications

2003 Medical Oncology
2003 Hematology
2000 Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Medicine, Division of Medical Oncology, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA, 2004-2006
Clinical Instructor,, Department of Medicine, Division Medical Oncology, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA, 2003-2004

Other Appointments/Responsibilities

Regular Faculty Member,, Member of The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 2007-2009

Honors and Awards

2002 Chief Fellow, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA
2002 Outstanding Fellow of the Year, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA
2002 Southwest Oncology Group, Young Investigators Training Course, Southwest Oncology Group
2000 Solomon Scholars Award for Outstanding Research During Residency, UCLA School of Medicine
1998 Solomon Scholars Award for Outstanding Research During Residency, UCLA School of Medicine
1992 Erasmus Scholarship, Granted by the European Community for Academic Excellence
1990-1991 Teaching Assistant in Anatomy, Madrid, Spain, Universidad Autonoma de Madrid
1988-1989 Outstanding Qualification for Final Research Project, International Baccalaureate Diploma

Selected Publications

Peer-Reviewed Original Research Articles
1. Jonasch E, Wood C,Matin S, Tu SM, Pagliaro L, Corn P, Aparicio A, Tamboli P, Millikan R, Wang X, Araujo J. Phase II presurgical feasibility study of benacizumab in untreated patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. In Press.
2. Jonasch E, Tannir N, Corn P, Warneke CL, Johnson M, Tamboli P, Ng C, Aparicio A, Ashe RG, Jonasch WD, Wright J. Upfront randomized phase II trial of sorafenib versus sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma. Cancer. In Press.
3. Tu SM, Lopez A, Leibovici D, Bilen MA, Evilyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate. Cancer. e-Pub 4/2009. PMID: 19402048.
4. Aparicio A, North B, Barske L, Wang X, Boliati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 4(3):1-9, 4/2009. PMID: 18981013.
5. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer:a California Cancer Consortium study. Clin Cancer Res 14(21):7138-42, 11/2008. PMID: 18272030.
6. Egger G, Aparicio AM, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res 67(1):346-53, 1/2007. PMID: 17210717.
7. Aparicio A. The potential of histone deacetylase inhibitors in lung cancer. Clin Lung Cancer 7(5)(5):309-12, 3/2006. PMID: 16640801.
8. Aparicio AM, Elkhouiery AB, Quinn DI. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am 32(2):217-30, 5/2005. PMID: 15862619.
9. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in Human Disease and Prospects for Epigenetic therapy. Nature 429(6990):457-63, 5/2004. PMID: 15164071.
10. Aparicio A, Eads C, Leong L, Laird PW, Newman N, Weber JS. Phase I Trial of continuous infusion 5-Aza-2'-deoxyctidine (DAC). Cancer Chemother Pharmacol 51(3):231-39, 3/2003. e-Pub 2/2003. PMID: 12655442.
11. Aparicio A, Chamberlain MC. Neoplastic meningitis. Curr Neurol Neurosci Rep 2(3):225-35, 5/2002. PMID: 11937001.
12. Aparicio A, Weber JS. Review of the clinical experience with 5-Azacytidine and 5-Aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs 3(4):627-33, 3/2002. PMID: 12090735.
13. Weber JS, Aparicio A. Novel immunologic approaches to the management of malignant melanoma. Curr Opin Oncol 13(2):124-28, 3/2001. PMID: 11224710.
14. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12(2):220-29, 2/1998. PMID: 9519785.
Other Articles
1. Sonpavde G, Aparicio A, Guttierez I, Boehm KA, Hutson TE, Berry WR, Asmar L, von Hoff DD. Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. Clin Genitourin Cancer 5(7):457-9, 12/2007.

Book Chapters
1. Logothetis CJ, Troncoso P, Kim J, Davis JW, Kuban DA, Mathew P, Aparicio A. In: Prostate Cancer. Cancer Medicine. 8th ed. Shelton, CT:PMPH-USA. In Press.
2. Millikan RE, Aparicio A, Sharma P. Experimental systemic therapy of metastatic urothelial cancer. In: In:UpToDate, Basow, DS(Ed), UpToDate, Waltham, MA. In Press.

Grant & Contract Support

Title: Biomarkers of Epigenetic Therapy
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 4/1/2008 - 3/31/2011
 
Title: Biologic Markers of Activity in Epigenetic Therapy in a Phase I Trial of Low Doses of Decitabine with Oral Sodium Phenylbutyrate in Patients with Solid Tumors
Funding Source: Wright Foundation
Role: Principal Investigator
Duration: 7/1/2004 - 6/1/2006

Last updated: 9/24/2009